Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › INAB

IN8bio

INAB Lead: Phase 1 4 Biotech Distilled articles ↓ 22 filings & releases ↓ Cash $14.2M (Sep 30, 2026) ↓ 4 verdicts ↓ 6 timing quotes ↓
ImmunologyOncology CellProtein

Market cap $10.0M 10.8M shares (10-Q, Nov 2, 2026) × $0.927 close Nov 6, 2026

Most recent annual filing: 2026-03-12

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. INB-400 FDA feedback2H 2026INB-400 FDA feedback, 2H 2026, major
  2. INB-100 enrollment doneLate 2026INB-100 enrollment done, Late 2026, notable
  3. INB-619 readoutBy year-end 2026INB-619 readout, By year-end 2026, notable
  4. INB-200/INB-400 Ph2 interimNov 2026INB-200/INB-400 Ph2 interim, Nov 2026, major
  5. Corporate financingApr 2027Corporate financing, Apr 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

DeltEx

Suite of gamma-delta T cell platform technologies encompassing TCEs, allogeneic, autologous, iPSC, and genetically modified cell therapy approaches designed to identify and eradicate tumor or target cells; applications in oncology and autoimmune diseases

INB-600

Novel gamma-delta T cell engager platform designed to selectively eliminate targets such as CD19, potentially reducing cytokine release syndrome and infections while expanding the therapeutic window compared with conventional CD3-targeting T cell engagers; applications across oncology and autoimmune indications

Targets: CD19

Discontinued (3)

Capital (as filed)

Cash
$14.2M cash, equivalents and restricted cash · Sep 30, 2026 (10-Q)
Operating cash flow
−$3.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$14.0M cash, runway April 2027 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on IN8bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-14 Watch IN8bio (INAB) - Scientific Deep Dive for Lead and Pipeline Products Compelling clinical efficacy in GBM and AML but severe near-term dilution gap and going-concern risk make the stock a watch until the balance sheet is permanently restructured.
  2. 2026-06-02 Speculative buy speculative UPDATE: IN8bio (INAB) - The Survival Curve Keeps Separating, and the ATM Spigot Just Turned On ASCO mOS update materially de-risks the scientific bull case with a +48% OS delta vs SOC and no DLTs/CRS, warranting a speculative entry sized for high volatility while the balance sheet remains managed but not solved.
  3. 2026-07-09 Speculative buy speculative UPDATE: IN8bio (INAB) - The JCO Stamp Lands, the Tape Ignores It JCO peer-reviewed publication is a genuine credentialing event that strengthens the FDA-dialogue posture for 2H 2026, while the 19% price decline appears driven by ATM mechanics rather than any thesis break.
  4. 2026-08-07 Watch UPDATE: IN8bio (INAB) - The Science Is Winning. The Listing Is the Problem. A new Nasdaq MVLS listing standard with no cure period, stock below $1.00, PIPE tranche out of reach, and ATM barely tapped shifts the risk from dilution to potential delisting — a structural risk that warrants stepping back to watch despite intact science.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (22)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)